Seres Therapeutics ( (MCRB) ) has issued an announcement.
Seres Therapeutics, Inc. shared promising results from their SER-155 Phase 1b study, indicating that the treatment led to a significant decrease in bloodstream infections and systemic antibiotic use in patients undergoing stem cell transplantation. The study, which aims to address the high risk of life-threatening bacterial infections in vulnerable patient groups, showed SER-155 was well-tolerated with a lower incidence of febrile neutropenia compared to placebo. These findings support the company’s strategy to advance the development of their live biotherapeutics platform, with plans to seek Breakthrough Therapy designation and discuss further development with the FDA.
For detailed information about MCRB stock, go to TipRanks’ Stock Analysis page.
